Effect of three calmodulin antagonists on subpopulations of CD44/CD24 immunophenotypes in breast cancer cell lines
AbstractPurpose: To determine the effect of three calmodulin antagonists (A-7, W-7 and W-13) on the subpopulations of CD44/CD24 immunophenotypes in MDA-MB-231 and MDA-MB-468 breast cancer cell lines.
Methods: Flow cytometry analysis was used to determine the proportion of the various subpopulations of the immunophenotypes, viz, CD44+CD24-, CD44-CD24+ and CD44+CD24+, when MDA-MB-231 and MDA-MB-468 cells were subjected to calmodulin antagonists. The effect of W-13 on the invasion properties of MDA-MB-231 and MDA-MB-468 was investigated using Matrigel invasion assay.
Results: A-7, W-7 and W-13 caused alterations in the subpopulation of CD44+CD24- in MDA-MB-231 cells. The most potent antagonist was W-13 as it reduced the proportion of tumorigenic CD44+CD24- to 0.64 ± 0.05 at a concentration of 80 μM. In contrast, the subpopulation of MDA-MB-468 cells, which had a low fraction of CD44+CD24-, was not altered when administered with W-7 but showed variations when incubated with W-13. Specifically, when the concentration of W-13 increased from 20 – 100 μM, the proportion of CD44+CD24+ was reduced from 92.93 ± 3.2 to 60.96 ± 2.4. The effect of W-13 on the subpopulations of CD44+CD24- and CD44+CD24+ in MDA-MB-231 and MDA-MB-468, respectively, reduced the invasion properties of the cells.
Conclusion: The calmodulin antagonist, W-13, has a significant antitumor effect on MDA-MB-231 and MDA-MB-468 breast cancer cells.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.